Trial supports new therapy for resistant rheumatoid arthritis

The new immunoglobulin G1 monoclonal antibody was associated with significant improvements in DAS28-CRP at 12 weeks.
The new immunoglobulin G1 monoclonal antibody was associated with significant improvements in DAS28-CRP at 12 weeks.
De bron die u probeert te openen is alleen beschikbaar voor geregistreerde gebruikers. Om verder te gaan kunt u inloggen of een GRATIS univadis ® account aanmaken.